Archivos espanoles de urologia · 2000
Treatment of retroperitoneal fibrosis with tamoxifen: case report and review of literature.
Клинический случайСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Puce R, Porcaro A B, Curti P, Girelli D, Pantalena M, Malossini G, Tallarigo C
Аннотация
OBJECTIVE: To evaluate the efficacy of tamoxifen in the treatment of idiopathic retroperitoneal fibrosis in one patient and to review the results reported in the literature.
METHODS: A 68-year-old man with idiopathic retroperitoneal fibrosis and obstructive acute renal failure was admitted to our department. Bilateral ureteral stents were placed and tamoxifen 20 mg daily p.o. was started.
RESULTS: The ureteral stents were removed five months after tamoxifen therapy. IVP demonstrated normal appearance of the ureters nine months after medical treatment. An MRI scan showed an important decrease of the fibrotic periaortic mass at 12 months and then we stopped tamoxifen.
CONCLUSIONS: Actually tamoxifen represents an attractive and safe choice of medical treatment for retroperitonea fibrosis, particularly in the acute stages. Nevertheless, the duration of treatment, the effectiveness and the persistence of the results are still uncertain because few cases have been reported in the literature.
METHODS: A 68-year-old man with idiopathic retroperitoneal fibrosis and obstructive acute renal failure was admitted to our department. Bilateral ureteral stents were placed and tamoxifen 20 mg daily p.o. was started.
RESULTS: The ureteral stents were removed five months after tamoxifen therapy. IVP demonstrated normal appearance of the ureters nine months after medical treatment. An MRI scan showed an important decrease of the fibrotic periaortic mass at 12 months and then we stopped tamoxifen.
CONCLUSIONS: Actually tamoxifen represents an attractive and safe choice of medical treatment for retroperitonea fibrosis, particularly in the acute stages. Nevertheless, the duration of treatment, the effectiveness and the persistence of the results are still uncertain because few cases have been reported in the literature.